Miromatrix Announces Participation in the 2022 American Transplant Congress
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the 2022 American Transplant Congress from June 4 to June 8, 2022. The company is focused on bioengineering fully transplantable organs, specifically human livers and kidneys, using a proprietary perfusion technology. This innovation aims to address the critical shortage of available human organs and enhance patient outcomes. Miromatrix’s unique approach positions it at the forefront of life sciences, potentially transforming organ transplantation.
- Participation in the 2022 American Transplant Congress highlights industry engagement.
- Proprietary perfusion technology may significantly improve organ transplant processes.
- None.
EDEN PRAIRIE, Minn., May 31, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming 2022 American Transplant Congress held on June 4th to June 8th, 2022.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
When is Miromatrix participating in the American Transplant Congress?
What technology is Miromatrix Medical focusing on?
What organs are being developed by Miromatrix Medical?
What is the ticker symbol for Miromatrix Medical?
